Investigator & Research Staff Resources

Proposals for Clinical Trials & Correlative Studies

Submit a New Study Concept

  • Proposals for clinical trials may be submitted from members of BMT CTN Core Centers, Affiliate Clinical Centers or others outside the Network.
  • Parties interested in submitting a proposal for consideration may complete the Proposed New Study Concept Form and return it to bmtctn@emmes.com.

Ancillary Studies and Secondary Data Analyses

An ancillary study entails the collection from study participants of data and/or specimens, or the conduct of additional analyses of existing materials or samples that are outside the specific objectives of the primary study. Information about Network ancillary studies can be found in the Manual of Procedures, Chapter 11; a summary of the ancillary study review and approval process is also available.

A secondary analysis uses previously collected data from BMT CTN studies to look at objectives other than those addressed in the original studies. Information about Network Ancillary Studies can be found in the Manual of Procedures, Chapter 12.

To assist in study planning, summaries of BMT CTN trial cohorts demographics and baseline characteristics are available.

To submit a correlative research proposal, please submit the completed BMT CTN Correlative Study Proposal form by email to bmtctn_nmdp@nmdp.org.

Please note that research materials (biospecimens and clinical data) will only be provided following proposal approval by the BMT CTN Executive Committee. Additional information may be found in the Manual of Procedures.

BMT CTN Research Sample Collections

The BMT CTN supports investigators engaged in retrospective immunogenetic and immunobiological studies in Hematopoietic cell transplantation (HCT) / Cellular Therapy (CT) by providing access to numerous research samples and clinical data collected during our BMT CTN clinical trials. Protocol-specific links provide investigators with the following resources:

  • Clinical protocols to review primary and secondary endpoints and other relevant clinical data collected in each trial.
  • Information regarding the prospective collection schedule for research samples, sample processing, and sample storage parameters.
  • Protocol-specific research sample collection summaries to facilitate initial assessments of available research samples for future ancillary study planning.
  • Overview of BMT CTN procedures for reviewing and approving ancillary study proposals and current proposal submission form.
BMT CTN 0101

A Randomized Double-blind Trial of Fluconazole vs. Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Recipients

NHLBI “Open Period” Status – NHLBI Repository: All inquiries for information regarding the availability of research samples and for clinical outcome data requests should be directed to the NHLBI by going to the following BioLINCC website page: https://biolincc.nhlbi.nih.gov/studies/bmtctn0101

BMT CTN 0102

A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients with Multiple Myeloma

NHLBI “Open Period” Status – NHLBI Repository: All inquiries for information regarding the availability of research samples and for clinical outcome data requests should be directed to the NHLBI by going to the following BioLINCC website page: https://biolincc.nhlbi.nih.gov/studies/bmtctn0102

BMT CTN 0201

A Phase III Randomized Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors

NHLBI “Open Period” Status – NHLBI Repository: All inquiries for information regarding the availability of research samples and for clinical outcome data requests should be directed to the NHLBI by going to the following BioLINCC website page: https://biolincc.nhlbi.nih.gov/studies/bmtctn0201

Donor Samples: This study also has a collection of donor specimens that are made available through the BMT CTN Repository.

BMT CTN 0302

Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination with Corticosteroids

BMT CTN 0401

Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

BMT CTN 0402

A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as GVHD Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation

NHLBI “Open Period” Status – NHLBI Repository: All inquiries for information regarding the availability of research samples and for clinical outcome data requests should be directed to the NHLBI by going to the following BioLINCC website page: https://biolincc.nhlbi.nih.gov/studies/bmtctn0402/?q=0402 

BMT CTN 0701

Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin’s Lymphoma Beyond First Complete Response

BMT CTN 0702

A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma

BMT CTN 07LT

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702

BMT CTN 0801

A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease

BMT CTN 0802

A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofetil vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD

BMT CTN 0803

High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients

ACSR Repository Biospecimen Collection: All inquiries for information regarding the availability of BMT CTN 0803 (AMC-071) research samples and associated clinical outcome data request should be directed to the AIDS and Cancer Specimen Resource Repository by going to the following ACSR website page: https://acsr.ucsf.edu

BMT CTN 0901

A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

BMT CTN 0903

Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-infected Patients

ACSR Repository Biospecimen Collection: All inquiries for information regarding the availability of BMT CTN 0903 (AMC-080) research samples and associated clinical outcome data request should be directed to the AIDS and Cancer Specimen Resource Repository by going to the following ACSR website page: https://acsr.ucsf.edu

BMT CTN 1101

A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies

BMT CTN 1102

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

BMT CTN 1202

Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT

CIBMTR-NMDP Research Sample Repository Sample Collection (Pre-Transplant Patient and Donor Samples Associated with BMT CTN 1202):

BMT CTN 1203

A Multi-Center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls

BMT CTN 1204

Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)

BMT CTN 1301

A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease

BMT CTN 1302

Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

BMT CTN 1401

Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions

BMT CTN 1501

A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease

BMT CTN 1502

Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP)

BMT CTN 1703/1801

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)

BMT CTN 1902

A Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide

BMT CTN 2002

A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

BMT CTN 2101

A Prospective Observational Study of The Immunogenicity of Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) after Autologous Hematopoietic Stem Cell Transplantation (HCT), Allogeneic HCT, and Chimeric Antigen Receptor T-Cell Therapy